Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives

The 21-day regimen of drospirenone-containing combined oral contraceptives is associated with similar risk of VTE compared to other combined oral contraceptives as well as potentially with a lower risk of ATE.